Antisense Therapeutics, Tianjin International Joint Academy of Biotechnology and Medicine deal

Antisense and the academy terminated a 2012 deal to form a JV in Hong Kong to develop Antisense's ATL1102 after the academy was unable to obtain required funding under the terms to form the JV. Antis...